Arcutis Biotherapeutics Inc (ARQT)
$10.07
Performance
- $10.00$10.50$10.07
0.7%
Downside
Day's Volatility :4.76%
Upside
4.1%
- $1.76$13.17$10.07
82.52%
Downside
52 Weeks Volatility :86.64%
Upside
23.54%
Returns
| Period | Arcutis Biotherapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 19.24% | 6.5% | 0.0% |
6 Months | 90.57% | 7.1% | 0.0% |
1 Year | -3.26% | 9.8% | 0.0% |
3 Years | -57.37% | 14.2% | -20.2% |
Highlights
Market Capitalization | 1.1B |
Book Value | $1.95 |
Earnings Per Share (EPS) | -2.79 |
Wall Street Target Price | 19.17 |
Profit Margin | -204.36% |
Operating Margin TTM | -63.79% |
Return On Assets TTM | -28.62% |
Return On Equity TTM | -119.24% |
Revenue TTM | 106.4M |
Revenue Per Share TTM | 1.3 |
Quarterly Revenue Growth YOY | 1682.4% |
Gross Profit TTM | 2.9M |
EBITDA | -194.9M |
Diluted Eps TTM | -2.79 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.9 |
EPS Estimate Next Year | -1.21 |
EPS Estimate Current Quarter | -0.73 |
EPS Estimate Next Quarter | -0.67 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 90.37%
Technicals Summary
Sell
Neutral
Buy
Arcutis Biotherapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Arcutis Biotherapeutics Inc | 8.72% | 90.57% | -3.26% | -57.37% | -53.67% |
 Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
 Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
 Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
 Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Arcutis Biotherapeutics Inc | NA | NA | NA | -1.9 | -1.19 | -0.29 | NA | 1.95 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Arcutis Biotherapeutics Inc | Buy | $1.1B | -53.67% | NA | -204.36% |
Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Arcutis Biotherapeutics Inc
Increasing Revenue
Revenue is up for the last 2 quarters, 13.52M → 49.56M (in $), with an average increase of 72.7% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -66.28M → -35.38M (in $), with an average increase of 87.3% per quarter
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 64.9%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 243.9%
Institutional Holdings
Jennison Associates LLC
10.52%State Street Corporation
7.59%Suvretta Capital Management, LLC
6.80%Rubric Capital Management LP
6.49%Polar Capital Holdings PLC
5.95%BlackRock Inc
5.75%
Company Information
arcutis biotherapeutics, inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. its lead product candidate is arq-151, a topical cream formulation of roflumilast that is in phase iii clinical trials for the treatment of plaque psoriasis and atopic dermatitis. the company is also developing arq-154, a topical foam formulation of arq-151 for the treatment of seborrheic dermatitis and scalp psoriasis; arq-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory dermatoses; and arq-255, a topical formulation of arq-252 designed to reach deeper into the skin to the postulated site of inflammation in alopecia areata. the company was formerly known as arcutis, inc. and changed its name to arcutis biotherapeutics, inc. in october 2019. arcutis biotherapeutics, inc. was founded in 2016 and is headquartered in westlake village, california.
Organization | Arcutis Biotherapeutics Inc |
Employees | 296 |
CEO | Mr. Todd Franklin Watanabe M.A. |
Industry | Health Technology |
Discover More
A Spac I Acquisition Corp
$10.07
-0.3%
Keyarch Acquisition Corp
$10.07
-0.3%
Connexa Sports Technologies Inc
$10.07
-0.3%
Us Value Etf
$10.07
-0.3%
First Wave Biopharma Inc
$10.07
-0.3%
Global X Msci Next Emerging
$10.07
-0.3%
Fat Projects Acquisition Corp
$10.07
-0.3%
Capital Link Global Fintech
$10.07
-0.3%
Applied Uv Inc
$10.07
-0.3%